Please assess the completion status of the following clinical trial:

Trial Title: Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endocrine tumour in the intestine or pancreas and with locally advanced or metastatic disease~* No hormone related symptoms~* Well or moderately differentiated tumour confirmed by histology~* Tumour lesions which are measurable by a CT or MRI scan~Exclusion Criteria:~* Previously treated with a somatostatin analogue unless more than 6 months ago and given for no more than 15 days~* Treated within the last 6 months with interferon, chemoembolisation or chemotherapy or at any time with a radionuclide~* Had a previous cancer except basal cell carcinoma and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for 5 years~* Pregnant or lactating~* Females must use adequate contraception during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lanreotide (Autogel formulation) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).